Inclusion Criteria:

1. All patients must have a diagnosis of CLL by immunophenotyping and flow cytometry analysis of blood or bone marrow.
2. Patients with Rai stage III-IV - OR - Patients with Rai stage 0-II (Appendix D) who meet one or more indication for treatment as defined by the NCI-sponsored Working Group are eligible for treatment on this protocol.
3. All patients must have a Zubrod performance status of 0-3 ( Appendix E )
4. Patients must receive treatment with fludarabine or alemtuzumab based regimens.
5. Patients must not have untreated or uncontrolled life-threatening infection.
6. Patients must sign informed consent.
7. Women of childbearing potential must have a negative serum pregnancy test and agree to use a medically accepted form of contraception from the time of initial screening through completion of the study.
8. No active CNS disease
9. Negative tests for HIV antibodies, Hepatitis B surface antigen, and Hepatitis C antibodies.

Exclusion Criteria:

1. Receipt of glucocorticoids (with the exception of inhaled glucocorticoid steroids for the use of allergic rhinitis or pulmonary disease) within 2 months prior to registration.
2. History of autoimmune disease unrelated to CLL (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosis). Autoimmune disease related to CLL, e.g. idiopathic thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia, is permitted if not requiring active treatment.
3. Subject Recruitment and Accrual Accrual is anticipated to take 12-15 months at a recruitment rate of approximately 1 patient per site per month. The expectation is that each site will recruit 50% of the target of 20 total evaluable patients. Subjects will be identified through the clinical practices of the investigator or sub investigators in the Division of Stem Cell Transplantation and Cell Therapy at MD Anderson and Division of Hematology-Oncology at both MD Anderson and UPENN.